Trial Profile
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Plamotamab (Primary) ; Plamotamab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Xencor
- 19 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2023 Planned number of patients changed from 160 to 270.
- 27 Feb 2023 Planned End Date changed from 1 Oct 2025 to 1 Jan 2025.